Global Personalized Cancer Medicine Market Growth (Status and Outlook) 2026-2032
The global Personalized Cancer Medicine market size is predicted to grow from US$ 209362 million in 2025 to US$ 483766 million in 2032; it is expected to grow at a CAGR of 13.0% from 2026 to 2032.
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.The average gross profit margin of this product is 78%.
Opportunities are driven by the higher response certainty enabled by biomarker-guided therapy and the forward shift of decision-making pathways. As broad molecular profiling and CDx become more embedded in routine practice, treatment selection increasingly moves from organ-based empiricism to molecular stratification, enabling better-matched first-line choices. Tumor-agnostic development further expands markets from “by organ” to “by target/biology,” increasing label-extension potential. Strengthening guideline and real-world consensus on “test first, treat next” supports synchronized growth of testing penetration and prescription accessibility.
Key constraints include evidence thresholds, stratification complexity, and payer sustainability. Biomarkers are not static—tumor heterogeneity, resistance evolution, and testing variability complicate population definition and benefit extrapolation. When access is CDx-dependent, drug and diagnostic registration, supply, and clinical pathways must move in lockstep; otherwise, “drug-ready but test-not-ready” bottlenecks emerge. In parallel, precision regimens often require more sophisticated management (AE handling, combinations, sequencing), raising the bar for standardized quality governance; without clear value evidence and coverage mechanisms, adoption cadence can fluctuate.
Demand is evolving from “finding an actionable target” to “full-cycle precision management.” Broad NGS and CDx are moving earlier in the disease course, refining perioperative and adjuvant decisions. Meanwhile, ctDNA/MRD-driven monitoring is gaining clinical relevance, enabling more real-time relapse-risk assessment, response evaluation, and resistance-mechanism identification—powering closed-loop “test–treat–retest” workflows. Providers increasingly pursue platformized capabilities that integrate molecular pathology, pharmacy governance, imaging, and longitudinal follow-up to build replicable precision-oncology systems and improve multidisciplinary efficiency and patient experience.
Upstream resembles a multi-technology biopharma supply chain. Small-molecule targeted drugs depend on key intermediates, chiral inputs, and high-purity solvent systems, with impurity control and scale-up consistency as the core. Biologics and ADCs rely on cell-line development, media/feed, single-use bioprocess systems, chromatography resins and filtration consumables, plus high-barrier linkers/payloads with stable supply. Cell and gene therapies extend further to plasmids, viral-vector inputs, cell-culture materials, and closed-system manufacturing consumables. As drugs become tightly coupled with diagnostics, upstream quality systems must also align with testing workflows (specimens, reference materials, and QA), making supply continuity and disciplined change control central to regulatory maintenance, commercialization ramp, and global delivery resilience.
LPI (LP Information)' newest research report, the “Personalized Cancer Medicine Industry Forecast” looks at past sales and reviews total world Personalized Cancer Medicine sales in 2025, providing a comprehensive analysis by region and market sector of projected Personalized Cancer Medicine sales for 2026 through 2032. With Personalized Cancer Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Cancer Medicine industry.
This Insight Report provides a comprehensive analysis of the global Personalized Cancer Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Personalized Cancer Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Personalized Cancer Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Cancer Medicine and breaks down the forecast by Method, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Cancer Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Cancer Medicine market by product type, application, key players and key regions and countries.
Segmentation by Method:
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.The average gross profit margin of this product is 78%.
Opportunities are driven by the higher response certainty enabled by biomarker-guided therapy and the forward shift of decision-making pathways. As broad molecular profiling and CDx become more embedded in routine practice, treatment selection increasingly moves from organ-based empiricism to molecular stratification, enabling better-matched first-line choices. Tumor-agnostic development further expands markets from “by organ” to “by target/biology,” increasing label-extension potential. Strengthening guideline and real-world consensus on “test first, treat next” supports synchronized growth of testing penetration and prescription accessibility.
Key constraints include evidence thresholds, stratification complexity, and payer sustainability. Biomarkers are not static—tumor heterogeneity, resistance evolution, and testing variability complicate population definition and benefit extrapolation. When access is CDx-dependent, drug and diagnostic registration, supply, and clinical pathways must move in lockstep; otherwise, “drug-ready but test-not-ready” bottlenecks emerge. In parallel, precision regimens often require more sophisticated management (AE handling, combinations, sequencing), raising the bar for standardized quality governance; without clear value evidence and coverage mechanisms, adoption cadence can fluctuate.
Demand is evolving from “finding an actionable target” to “full-cycle precision management.” Broad NGS and CDx are moving earlier in the disease course, refining perioperative and adjuvant decisions. Meanwhile, ctDNA/MRD-driven monitoring is gaining clinical relevance, enabling more real-time relapse-risk assessment, response evaluation, and resistance-mechanism identification—powering closed-loop “test–treat–retest” workflows. Providers increasingly pursue platformized capabilities that integrate molecular pathology, pharmacy governance, imaging, and longitudinal follow-up to build replicable precision-oncology systems and improve multidisciplinary efficiency and patient experience.
Upstream resembles a multi-technology biopharma supply chain. Small-molecule targeted drugs depend on key intermediates, chiral inputs, and high-purity solvent systems, with impurity control and scale-up consistency as the core. Biologics and ADCs rely on cell-line development, media/feed, single-use bioprocess systems, chromatography resins and filtration consumables, plus high-barrier linkers/payloads with stable supply. Cell and gene therapies extend further to plasmids, viral-vector inputs, cell-culture materials, and closed-system manufacturing consumables. As drugs become tightly coupled with diagnostics, upstream quality systems must also align with testing workflows (specimens, reference materials, and QA), making supply continuity and disciplined change control central to regulatory maintenance, commercialization ramp, and global delivery resilience.
LPI (LP Information)' newest research report, the “Personalized Cancer Medicine Industry Forecast” looks at past sales and reviews total world Personalized Cancer Medicine sales in 2025, providing a comprehensive analysis by region and market sector of projected Personalized Cancer Medicine sales for 2026 through 2032. With Personalized Cancer Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Cancer Medicine industry.
This Insight Report provides a comprehensive analysis of the global Personalized Cancer Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Personalized Cancer Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Personalized Cancer Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Cancer Medicine and breaks down the forecast by Method, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Cancer Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Cancer Medicine market by product type, application, key players and key regions and countries.
Segmentation by Method:
- Cancer Immunotherapy
- Targeted Therapy
- Injection
- Oral
- Other
- Small-molecule Targeted Therapies
- Antibody Therapies
- Biomarker-guided Checkpoint Inhibitors
- Antibody–drug Conjugates
- Cell & Gene Therapies
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Blood-related Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AbbVie
- Johnson & Johnson
- Novartis
- Gilead Sciences
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Merck & Co
- Takeda
- Merck KGaA
- Seagen
- Eli Lilly
- Ono Pharmaceutical
- Pfizer
- GSK
- Exelixis
- Regeneron
- Innovent
- Hengrui Medicine
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Personalized Cancer Medicine Market Size (2021-2032)
2.1.2 Personalized Cancer Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Personalized Cancer Medicine by Country/Region (2021, 2025 & 2032)
2.2 Personalized Cancer Medicine Segment by Method
2.2.1 Cancer Immunotherapy
2.2.2 Targeted Therapy
2.2.3 Personalized Cancer Medicine Market Size by Method
2.2.3.1 Personalized Cancer Medicine Market Size CAGR by Method (2021 VS 2025 VS 2032)
2.2.3.2 Global Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
2.3 Personalized Cancer Medicine Segment by Route of Administration
2.3.1 Injection
2.3.2 Oral
2.3.3 Other
2.3.4 Personalized Cancer Medicine Market Size by Route of Administration
2.3.4.1 Personalized Cancer Medicine Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.3.4.2 Global Personalized Cancer Medicine Market Size Market Share by Route of Administration (2021-2026)
2.4 Personalized Cancer Medicine Segment by Therapeutic Modality
2.4.1 Small-molecule Targeted Therapies
2.4.2 Antibody Therapies
2.4.3 Biomarker-guided Checkpoint Inhibitors
2.4.4 Antibody–drug Conjugates
2.4.5 Cell & Gene Therapies
2.4.6 Personalized Cancer Medicine Market Size by Therapeutic Modality
2.4.6.1 Personalized Cancer Medicine Market Size CAGR by Therapeutic Modality (2021 VS 2025 VS 2032)
2.4.6.2 Global Personalized Cancer Medicine Market Size Market Share by Therapeutic Modality (2021-2026)
2.5 Personalized Cancer Medicine Segment by Application
2.5.1 Lung Cancer
2.5.2 Breast Cancer
2.5.3 Prostate Cancer
2.5.4 Blood-related Cancer
2.5.5 Other
2.5.6 Personalized Cancer Medicine Market Size by Application
2.5.6.1 Personalized Cancer Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.6.2 Global Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
3 PERSONALIZED CANCER MEDICINE MARKET SIZE BY PLAYER
3.1 Personalized Cancer Medicine Market Size Market Share by Player
3.1.1 Global Personalized Cancer Medicine Revenue by Player (2021-2026)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Player (2021-2026)
3.2 Global Personalized Cancer Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PERSONALIZED CANCER MEDICINE BY REGION
4.1 Personalized Cancer Medicine Market Size by Region (2021-2026)
4.2 Global Personalized Cancer Medicine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Personalized Cancer Medicine Market Size Growth (2021-2026)
4.4 APAC Personalized Cancer Medicine Market Size Growth (2021-2026)
4.5 Europe Personalized Cancer Medicine Market Size Growth (2021-2026)
4.6 Middle East & Africa Personalized Cancer Medicine Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Personalized Cancer Medicine Market Size by Country (2021-2026)
5.2 Americas Personalized Cancer Medicine Market Size by Method (2021-2026)
5.3 Americas Personalized Cancer Medicine Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Personalized Cancer Medicine Market Size by Region (2021-2026)
6.2 APAC Personalized Cancer Medicine Market Size by Method (2021-2026)
6.3 APAC Personalized Cancer Medicine Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Personalized Cancer Medicine Market Size by Country (2021-2026)
7.2 Europe Personalized Cancer Medicine Market Size by Method (2021-2026)
7.3 Europe Personalized Cancer Medicine Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Personalized Cancer Medicine by Region (2021-2026)
8.2 Middle East & Africa Personalized Cancer Medicine Market Size by Method (2021-2026)
8.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PERSONALIZED CANCER MEDICINE MARKET FORECAST
10.1 Global Personalized Cancer Medicine Forecast by Region (2027-2032)
10.1.1 Global Personalized Cancer Medicine Forecast by Region (2027-2032)
10.1.2 Americas Personalized Cancer Medicine Forecast
10.1.3 APAC Personalized Cancer Medicine Forecast
10.1.4 Europe Personalized Cancer Medicine Forecast
10.1.5 Middle East & Africa Personalized Cancer Medicine Forecast
10.2 Americas Personalized Cancer Medicine Forecast by Country (2027-2032)
10.2.1 United States Market Personalized Cancer Medicine Forecast
10.2.2 Canada Market Personalized Cancer Medicine Forecast
10.2.3 Mexico Market Personalized Cancer Medicine Forecast
10.2.4 Brazil Market Personalized Cancer Medicine Forecast
10.3 APAC Personalized Cancer Medicine Forecast by Region (2027-2032)
10.3.1 China Personalized Cancer Medicine Market Forecast
10.3.2 Japan Market Personalized Cancer Medicine Forecast
10.3.3 Korea Market Personalized Cancer Medicine Forecast
10.3.4 Southeast Asia Market Personalized Cancer Medicine Forecast
10.3.5 India Market Personalized Cancer Medicine Forecast
10.3.6 Australia Market Personalized Cancer Medicine Forecast
10.4 Europe Personalized Cancer Medicine Forecast by Country (2027-2032)
10.4.1 Germany Market Personalized Cancer Medicine Forecast
10.4.2 France Market Personalized Cancer Medicine Forecast
10.4.3 UK Market Personalized Cancer Medicine Forecast
10.4.4 Italy Market Personalized Cancer Medicine Forecast
10.4.5 Russia Market Personalized Cancer Medicine Forecast
10.5 Middle East & Africa Personalized Cancer Medicine Forecast by Region (2027-2032)
10.5.1 Egypt Market Personalized Cancer Medicine Forecast
10.5.2 South Africa Market Personalized Cancer Medicine Forecast
10.5.3 Israel Market Personalized Cancer Medicine Forecast
10.5.4 Turkey Market Personalized Cancer Medicine Forecast
10.6 Global Personalized Cancer Medicine Forecast by Method (2027-2032)
10.7 Global Personalized Cancer Medicine Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Personalized Cancer Medicine Forecast
11 KEY PLAYERS ANALYSIS
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Personalized Cancer Medicine Product Offered
11.1.3 AbbVie Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Personalized Cancer Medicine Product Offered
11.2.3 Johnson & Johnson Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Personalized Cancer Medicine Product Offered
11.3.3 Novartis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Information
11.4.2 Gilead Sciences Personalized Cancer Medicine Product Offered
11.4.3 Gilead Sciences Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Gilead Sciences Main Business Overview
11.4.5 Gilead Sciences Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Personalized Cancer Medicine Product Offered
11.5.3 Roche Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Personalized Cancer Medicine Product Offered
11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Personalized Cancer Medicine Product Offered
11.7.3 Amgen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Amgen Main Business Overview
11.7.5 Amgen Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Personalized Cancer Medicine Product Offered
11.8.3 AstraZeneca Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Merck & Co
11.9.1 Merck & Co Company Information
11.9.2 Merck & Co Personalized Cancer Medicine Product Offered
11.9.3 Merck & Co Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Merck & Co Main Business Overview
11.9.5 Merck & Co Latest Developments
11.10 Takeda
11.10.1 Takeda Company Information
11.10.2 Takeda Personalized Cancer Medicine Product Offered
11.10.3 Takeda Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Takeda Main Business Overview
11.10.5 Takeda Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Personalized Cancer Medicine Product Offered
11.11.3 Merck KGaA Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Seagen
11.12.1 Seagen Company Information
11.12.2 Seagen Personalized Cancer Medicine Product Offered
11.12.3 Seagen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Seagen Main Business Overview
11.12.5 Seagen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Personalized Cancer Medicine Product Offered
11.13.3 Eli Lilly Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Information
11.14.2 Ono Pharmaceutical Personalized Cancer Medicine Product Offered
11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Ono Pharmaceutical Main Business Overview
11.14.5 Ono Pharmaceutical Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Personalized Cancer Medicine Product Offered
11.15.3 Pfizer Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 GSK
11.16.1 GSK Company Information
11.16.2 GSK Personalized Cancer Medicine Product Offered
11.16.3 GSK Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 GSK Main Business Overview
11.16.5 GSK Latest Developments
11.17 Exelixis
11.17.1 Exelixis Company Information
11.17.2 Exelixis Personalized Cancer Medicine Product Offered
11.17.3 Exelixis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Exelixis Main Business Overview
11.17.5 Exelixis Latest Developments
11.18 Regeneron
11.18.1 Regeneron Company Information
11.18.2 Regeneron Personalized Cancer Medicine Product Offered
11.18.3 Regeneron Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Regeneron Main Business Overview
11.18.5 Regeneron Latest Developments
11.19 Innovent
11.19.1 Innovent Company Information
11.19.2 Innovent Personalized Cancer Medicine Product Offered
11.19.3 Innovent Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Innovent Main Business Overview
11.19.5 Innovent Latest Developments
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Information
11.20.2 Hengrui Medicine Personalized Cancer Medicine Product Offered
11.20.3 Hengrui Medicine Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Hengrui Medicine Main Business Overview
11.20.5 Hengrui Medicine Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Personalized Cancer Medicine Market Size (2021-2032)
2.1.2 Personalized Cancer Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Personalized Cancer Medicine by Country/Region (2021, 2025 & 2032)
2.2 Personalized Cancer Medicine Segment by Method
2.2.1 Cancer Immunotherapy
2.2.2 Targeted Therapy
2.2.3 Personalized Cancer Medicine Market Size by Method
2.2.3.1 Personalized Cancer Medicine Market Size CAGR by Method (2021 VS 2025 VS 2032)
2.2.3.2 Global Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
2.3 Personalized Cancer Medicine Segment by Route of Administration
2.3.1 Injection
2.3.2 Oral
2.3.3 Other
2.3.4 Personalized Cancer Medicine Market Size by Route of Administration
2.3.4.1 Personalized Cancer Medicine Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.3.4.2 Global Personalized Cancer Medicine Market Size Market Share by Route of Administration (2021-2026)
2.4 Personalized Cancer Medicine Segment by Therapeutic Modality
2.4.1 Small-molecule Targeted Therapies
2.4.2 Antibody Therapies
2.4.3 Biomarker-guided Checkpoint Inhibitors
2.4.4 Antibody–drug Conjugates
2.4.5 Cell & Gene Therapies
2.4.6 Personalized Cancer Medicine Market Size by Therapeutic Modality
2.4.6.1 Personalized Cancer Medicine Market Size CAGR by Therapeutic Modality (2021 VS 2025 VS 2032)
2.4.6.2 Global Personalized Cancer Medicine Market Size Market Share by Therapeutic Modality (2021-2026)
2.5 Personalized Cancer Medicine Segment by Application
2.5.1 Lung Cancer
2.5.2 Breast Cancer
2.5.3 Prostate Cancer
2.5.4 Blood-related Cancer
2.5.5 Other
2.5.6 Personalized Cancer Medicine Market Size by Application
2.5.6.1 Personalized Cancer Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.6.2 Global Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
3 PERSONALIZED CANCER MEDICINE MARKET SIZE BY PLAYER
3.1 Personalized Cancer Medicine Market Size Market Share by Player
3.1.1 Global Personalized Cancer Medicine Revenue by Player (2021-2026)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Player (2021-2026)
3.2 Global Personalized Cancer Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PERSONALIZED CANCER MEDICINE BY REGION
4.1 Personalized Cancer Medicine Market Size by Region (2021-2026)
4.2 Global Personalized Cancer Medicine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Personalized Cancer Medicine Market Size Growth (2021-2026)
4.4 APAC Personalized Cancer Medicine Market Size Growth (2021-2026)
4.5 Europe Personalized Cancer Medicine Market Size Growth (2021-2026)
4.6 Middle East & Africa Personalized Cancer Medicine Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Personalized Cancer Medicine Market Size by Country (2021-2026)
5.2 Americas Personalized Cancer Medicine Market Size by Method (2021-2026)
5.3 Americas Personalized Cancer Medicine Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Personalized Cancer Medicine Market Size by Region (2021-2026)
6.2 APAC Personalized Cancer Medicine Market Size by Method (2021-2026)
6.3 APAC Personalized Cancer Medicine Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Personalized Cancer Medicine Market Size by Country (2021-2026)
7.2 Europe Personalized Cancer Medicine Market Size by Method (2021-2026)
7.3 Europe Personalized Cancer Medicine Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Personalized Cancer Medicine by Region (2021-2026)
8.2 Middle East & Africa Personalized Cancer Medicine Market Size by Method (2021-2026)
8.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PERSONALIZED CANCER MEDICINE MARKET FORECAST
10.1 Global Personalized Cancer Medicine Forecast by Region (2027-2032)
10.1.1 Global Personalized Cancer Medicine Forecast by Region (2027-2032)
10.1.2 Americas Personalized Cancer Medicine Forecast
10.1.3 APAC Personalized Cancer Medicine Forecast
10.1.4 Europe Personalized Cancer Medicine Forecast
10.1.5 Middle East & Africa Personalized Cancer Medicine Forecast
10.2 Americas Personalized Cancer Medicine Forecast by Country (2027-2032)
10.2.1 United States Market Personalized Cancer Medicine Forecast
10.2.2 Canada Market Personalized Cancer Medicine Forecast
10.2.3 Mexico Market Personalized Cancer Medicine Forecast
10.2.4 Brazil Market Personalized Cancer Medicine Forecast
10.3 APAC Personalized Cancer Medicine Forecast by Region (2027-2032)
10.3.1 China Personalized Cancer Medicine Market Forecast
10.3.2 Japan Market Personalized Cancer Medicine Forecast
10.3.3 Korea Market Personalized Cancer Medicine Forecast
10.3.4 Southeast Asia Market Personalized Cancer Medicine Forecast
10.3.5 India Market Personalized Cancer Medicine Forecast
10.3.6 Australia Market Personalized Cancer Medicine Forecast
10.4 Europe Personalized Cancer Medicine Forecast by Country (2027-2032)
10.4.1 Germany Market Personalized Cancer Medicine Forecast
10.4.2 France Market Personalized Cancer Medicine Forecast
10.4.3 UK Market Personalized Cancer Medicine Forecast
10.4.4 Italy Market Personalized Cancer Medicine Forecast
10.4.5 Russia Market Personalized Cancer Medicine Forecast
10.5 Middle East & Africa Personalized Cancer Medicine Forecast by Region (2027-2032)
10.5.1 Egypt Market Personalized Cancer Medicine Forecast
10.5.2 South Africa Market Personalized Cancer Medicine Forecast
10.5.3 Israel Market Personalized Cancer Medicine Forecast
10.5.4 Turkey Market Personalized Cancer Medicine Forecast
10.6 Global Personalized Cancer Medicine Forecast by Method (2027-2032)
10.7 Global Personalized Cancer Medicine Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Personalized Cancer Medicine Forecast
11 KEY PLAYERS ANALYSIS
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Personalized Cancer Medicine Product Offered
11.1.3 AbbVie Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Personalized Cancer Medicine Product Offered
11.2.3 Johnson & Johnson Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Personalized Cancer Medicine Product Offered
11.3.3 Novartis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Information
11.4.2 Gilead Sciences Personalized Cancer Medicine Product Offered
11.4.3 Gilead Sciences Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Gilead Sciences Main Business Overview
11.4.5 Gilead Sciences Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Personalized Cancer Medicine Product Offered
11.5.3 Roche Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Personalized Cancer Medicine Product Offered
11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Personalized Cancer Medicine Product Offered
11.7.3 Amgen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Amgen Main Business Overview
11.7.5 Amgen Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Personalized Cancer Medicine Product Offered
11.8.3 AstraZeneca Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Merck & Co
11.9.1 Merck & Co Company Information
11.9.2 Merck & Co Personalized Cancer Medicine Product Offered
11.9.3 Merck & Co Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Merck & Co Main Business Overview
11.9.5 Merck & Co Latest Developments
11.10 Takeda
11.10.1 Takeda Company Information
11.10.2 Takeda Personalized Cancer Medicine Product Offered
11.10.3 Takeda Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Takeda Main Business Overview
11.10.5 Takeda Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Personalized Cancer Medicine Product Offered
11.11.3 Merck KGaA Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Seagen
11.12.1 Seagen Company Information
11.12.2 Seagen Personalized Cancer Medicine Product Offered
11.12.3 Seagen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Seagen Main Business Overview
11.12.5 Seagen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Personalized Cancer Medicine Product Offered
11.13.3 Eli Lilly Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Information
11.14.2 Ono Pharmaceutical Personalized Cancer Medicine Product Offered
11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Ono Pharmaceutical Main Business Overview
11.14.5 Ono Pharmaceutical Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Personalized Cancer Medicine Product Offered
11.15.3 Pfizer Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 GSK
11.16.1 GSK Company Information
11.16.2 GSK Personalized Cancer Medicine Product Offered
11.16.3 GSK Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 GSK Main Business Overview
11.16.5 GSK Latest Developments
11.17 Exelixis
11.17.1 Exelixis Company Information
11.17.2 Exelixis Personalized Cancer Medicine Product Offered
11.17.3 Exelixis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Exelixis Main Business Overview
11.17.5 Exelixis Latest Developments
11.18 Regeneron
11.18.1 Regeneron Company Information
11.18.2 Regeneron Personalized Cancer Medicine Product Offered
11.18.3 Regeneron Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Regeneron Main Business Overview
11.18.5 Regeneron Latest Developments
11.19 Innovent
11.19.1 Innovent Company Information
11.19.2 Innovent Personalized Cancer Medicine Product Offered
11.19.3 Innovent Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Innovent Main Business Overview
11.19.5 Innovent Latest Developments
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Information
11.20.2 Hengrui Medicine Personalized Cancer Medicine Product Offered
11.20.3 Hengrui Medicine Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Hengrui Medicine Main Business Overview
11.20.5 Hengrui Medicine Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Personalized Cancer Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Personalized Cancer Medicine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cancer Immunotherapy
Table 4. Major Players of Targeted Therapy
Table 5. Personalized Cancer Medicine Market Size CAGR by Method (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 7. Global Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Table 8. Major Players of Injection
Table 9. Major Players of Oral
Table 10. Major Players of Other
Table 11. Personalized Cancer Medicine Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Personalized Cancer Medicine Market Size by Route of Administration (2021-2026) & ($ millions)
Table 13. Global Personalized Cancer Medicine Market Size Market Share by Route of Administration (2021-2026)
Table 14. Major Players of Small-molecule Targeted Therapies
Table 15. Major Players of Antibody Therapies
Table 16. Major Players of Biomarker-guided Checkpoint Inhibitors
Table 17. Major Players of Antibody–drug Conjugates
Table 18. Major Players of Cell & Gene Therapies
Table 19. Personalized Cancer Medicine Market Size CAGR by Therapeutic Modality (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global Personalized Cancer Medicine Market Size by Therapeutic Modality (2021-2026) & ($ millions)
Table 21. Global Personalized Cancer Medicine Market Size Market Share by Therapeutic Modality (2021-2026)
Table 22. Personalized Cancer Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 24. Global Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Table 25. Global Personalized Cancer Medicine Revenue by Player (2021-2026) & ($ millions)
Table 26. Global Personalized Cancer Medicine Revenue Market Share by Player (2021-2026)
Table 27. Personalized Cancer Medicine Key Players Head office and Products Offered
Table 28. Personalized Cancer Medicine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Personalized Cancer Medicine Market Size by Region (2021-2026) & ($ millions)
Table 32. Global Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Table 33. Global Personalized Cancer Medicine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Personalized Cancer Medicine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Personalized Cancer Medicine Market Size by Country (2021-2026) & ($ millions)
Table 36. Americas Personalized Cancer Medicine Market Size Market Share by Country (2021-2026)
Table 37. Americas Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 38. Americas Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Table 39. Americas Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 40. Americas Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Table 41. APAC Personalized Cancer Medicine Market Size by Region (2021-2026) & ($ millions)
Table 42. APAC Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Table 43. APAC Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 44. APAC Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 45. Europe Personalized Cancer Medicine Market Size by Country (2021-2026) & ($ millions)
Table 46. Europe Personalized Cancer Medicine Market Size Market Share by Country (2021-2026)
Table 47. Europe Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 48. Europe Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 49. Middle East & Africa Personalized Cancer Medicine Market Size by Region (2021-2026) & ($ millions)
Table 50. Middle East & Africa Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 51. Middle East & Africa Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 52. Key Market Drivers & Growth Opportunities of Personalized Cancer Medicine
Table 53. Key Market Challenges & Risks of Personalized Cancer Medicine
Table 54. Key Industry Trends of Personalized Cancer Medicine
Table 55. Global Personalized Cancer Medicine Market Size Forecast by Region (2027-2032) & ($ millions)
Table 56. Global Personalized Cancer Medicine Market Size Market Share Forecast by Region (2027-2032)
Table 57. Global Personalized Cancer Medicine Market Size Forecast by Method (2027-2032) & ($ millions)
Table 58. Global Personalized Cancer Medicine Market Size Forecast by Application (2027-2032) & ($ millions)
Table 59. AbbVie Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 60. AbbVie Personalized Cancer Medicine Product Offered
Table 61. AbbVie Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. AbbVie Main Business
Table 63. AbbVie Latest Developments
Table 64. Johnson & Johnson Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 65. Johnson & Johnson Personalized Cancer Medicine Product Offered
Table 66. Johnson & Johnson Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Johnson & Johnson Main Business
Table 68. Johnson & Johnson Latest Developments
Table 69. Novartis Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 70. Novartis Personalized Cancer Medicine Product Offered
Table 71. Novartis Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Novartis Main Business
Table 73. Novartis Latest Developments
Table 74. Gilead Sciences Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 75. Gilead Sciences Personalized Cancer Medicine Product Offered
Table 76. Gilead Sciences Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Gilead Sciences Main Business
Table 78. Gilead Sciences Latest Developments
Table 79. Roche Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 80. Roche Personalized Cancer Medicine Product Offered
Table 81. Roche Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Roche Main Business
Table 83. Roche Latest Developments
Table 84. Bristol-Myers Squibb Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 85. Bristol-Myers Squibb Personalized Cancer Medicine Product Offered
Table 86. Bristol-Myers Squibb Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Bristol-Myers Squibb Main Business
Table 88. Bristol-Myers Squibb Latest Developments
Table 89. Amgen Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 90. Amgen Personalized Cancer Medicine Product Offered
Table 91. Amgen Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Amgen Main Business
Table 93. Amgen Latest Developments
Table 94. AstraZeneca Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 95. AstraZeneca Personalized Cancer Medicine Product Offered
Table 96. AstraZeneca Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. AstraZeneca Main Business
Table 98. AstraZeneca Latest Developments
Table 99. Merck & Co Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 100. Merck & Co Personalized Cancer Medicine Product Offered
Table 101. Merck & Co Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. Merck & Co Main Business
Table 103. Merck & Co Latest Developments
Table 104. Takeda Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 105. Takeda Personalized Cancer Medicine Product Offered
Table 106. Takeda Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Takeda Main Business
Table 108. Takeda Latest Developments
Table 109. Merck KGaA Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 110. Merck KGaA Personalized Cancer Medicine Product Offered
Table 111. Merck KGaA Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. Merck KGaA Main Business
Table 113. Merck KGaA Latest Developments
Table 114. Seagen Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 115. Seagen Personalized Cancer Medicine Product Offered
Table 116. Seagen Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Seagen Main Business
Table 118. Seagen Latest Developments
Table 119. Eli Lilly Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 120. Eli Lilly Personalized Cancer Medicine Product Offered
Table 121. Eli Lilly Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Eli Lilly Main Business
Table 123. Eli Lilly Latest Developments
Table 124. Ono Pharmaceutical Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 125. Ono Pharmaceutical Personalized Cancer Medicine Product Offered
Table 126. Ono Pharmaceutical Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Ono Pharmaceutical Main Business
Table 128. Ono Pharmaceutical Latest Developments
Table 129. Pfizer Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 130. Pfizer Personalized Cancer Medicine Product Offered
Table 131. Pfizer Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. Pfizer Main Business
Table 133. Pfizer Latest Developments
Table 134. GSK Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 135. GSK Personalized Cancer Medicine Product Offered
Table 136. GSK Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. GSK Main Business
Table 138. GSK Latest Developments
Table 139. Exelixis Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 140. Exelixis Personalized Cancer Medicine Product Offered
Table 141. Exelixis Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. Exelixis Main Business
Table 143. Exelixis Latest Developments
Table 144. Regeneron Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 145. Regeneron Personalized Cancer Medicine Product Offered
Table 146. Regeneron Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. Regeneron Main Business
Table 148. Regeneron Latest Developments
Table 149. Innovent Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 150. Innovent Personalized Cancer Medicine Product Offered
Table 151. Innovent Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. Innovent Main Business
Table 153. Innovent Latest Developments
Table 154. Hengrui Medicine Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 155. Hengrui Medicine Personalized Cancer Medicine Product Offered
Table 156. Hengrui Medicine Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Hengrui Medicine Main Business
Table 158. Hengrui Medicine Latest Developments
Table 1. Personalized Cancer Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Personalized Cancer Medicine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cancer Immunotherapy
Table 4. Major Players of Targeted Therapy
Table 5. Personalized Cancer Medicine Market Size CAGR by Method (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 7. Global Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Table 8. Major Players of Injection
Table 9. Major Players of Oral
Table 10. Major Players of Other
Table 11. Personalized Cancer Medicine Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Personalized Cancer Medicine Market Size by Route of Administration (2021-2026) & ($ millions)
Table 13. Global Personalized Cancer Medicine Market Size Market Share by Route of Administration (2021-2026)
Table 14. Major Players of Small-molecule Targeted Therapies
Table 15. Major Players of Antibody Therapies
Table 16. Major Players of Biomarker-guided Checkpoint Inhibitors
Table 17. Major Players of Antibody–drug Conjugates
Table 18. Major Players of Cell & Gene Therapies
Table 19. Personalized Cancer Medicine Market Size CAGR by Therapeutic Modality (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global Personalized Cancer Medicine Market Size by Therapeutic Modality (2021-2026) & ($ millions)
Table 21. Global Personalized Cancer Medicine Market Size Market Share by Therapeutic Modality (2021-2026)
Table 22. Personalized Cancer Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 24. Global Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Table 25. Global Personalized Cancer Medicine Revenue by Player (2021-2026) & ($ millions)
Table 26. Global Personalized Cancer Medicine Revenue Market Share by Player (2021-2026)
Table 27. Personalized Cancer Medicine Key Players Head office and Products Offered
Table 28. Personalized Cancer Medicine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Personalized Cancer Medicine Market Size by Region (2021-2026) & ($ millions)
Table 32. Global Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Table 33. Global Personalized Cancer Medicine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Personalized Cancer Medicine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Personalized Cancer Medicine Market Size by Country (2021-2026) & ($ millions)
Table 36. Americas Personalized Cancer Medicine Market Size Market Share by Country (2021-2026)
Table 37. Americas Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 38. Americas Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Table 39. Americas Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 40. Americas Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Table 41. APAC Personalized Cancer Medicine Market Size by Region (2021-2026) & ($ millions)
Table 42. APAC Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Table 43. APAC Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 44. APAC Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 45. Europe Personalized Cancer Medicine Market Size by Country (2021-2026) & ($ millions)
Table 46. Europe Personalized Cancer Medicine Market Size Market Share by Country (2021-2026)
Table 47. Europe Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 48. Europe Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 49. Middle East & Africa Personalized Cancer Medicine Market Size by Region (2021-2026) & ($ millions)
Table 50. Middle East & Africa Personalized Cancer Medicine Market Size by Method (2021-2026) & ($ millions)
Table 51. Middle East & Africa Personalized Cancer Medicine Market Size by Application (2021-2026) & ($ millions)
Table 52. Key Market Drivers & Growth Opportunities of Personalized Cancer Medicine
Table 53. Key Market Challenges & Risks of Personalized Cancer Medicine
Table 54. Key Industry Trends of Personalized Cancer Medicine
Table 55. Global Personalized Cancer Medicine Market Size Forecast by Region (2027-2032) & ($ millions)
Table 56. Global Personalized Cancer Medicine Market Size Market Share Forecast by Region (2027-2032)
Table 57. Global Personalized Cancer Medicine Market Size Forecast by Method (2027-2032) & ($ millions)
Table 58. Global Personalized Cancer Medicine Market Size Forecast by Application (2027-2032) & ($ millions)
Table 59. AbbVie Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 60. AbbVie Personalized Cancer Medicine Product Offered
Table 61. AbbVie Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. AbbVie Main Business
Table 63. AbbVie Latest Developments
Table 64. Johnson & Johnson Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 65. Johnson & Johnson Personalized Cancer Medicine Product Offered
Table 66. Johnson & Johnson Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Johnson & Johnson Main Business
Table 68. Johnson & Johnson Latest Developments
Table 69. Novartis Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 70. Novartis Personalized Cancer Medicine Product Offered
Table 71. Novartis Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Novartis Main Business
Table 73. Novartis Latest Developments
Table 74. Gilead Sciences Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 75. Gilead Sciences Personalized Cancer Medicine Product Offered
Table 76. Gilead Sciences Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Gilead Sciences Main Business
Table 78. Gilead Sciences Latest Developments
Table 79. Roche Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 80. Roche Personalized Cancer Medicine Product Offered
Table 81. Roche Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Roche Main Business
Table 83. Roche Latest Developments
Table 84. Bristol-Myers Squibb Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 85. Bristol-Myers Squibb Personalized Cancer Medicine Product Offered
Table 86. Bristol-Myers Squibb Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Bristol-Myers Squibb Main Business
Table 88. Bristol-Myers Squibb Latest Developments
Table 89. Amgen Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 90. Amgen Personalized Cancer Medicine Product Offered
Table 91. Amgen Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Amgen Main Business
Table 93. Amgen Latest Developments
Table 94. AstraZeneca Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 95. AstraZeneca Personalized Cancer Medicine Product Offered
Table 96. AstraZeneca Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. AstraZeneca Main Business
Table 98. AstraZeneca Latest Developments
Table 99. Merck & Co Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 100. Merck & Co Personalized Cancer Medicine Product Offered
Table 101. Merck & Co Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. Merck & Co Main Business
Table 103. Merck & Co Latest Developments
Table 104. Takeda Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 105. Takeda Personalized Cancer Medicine Product Offered
Table 106. Takeda Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Takeda Main Business
Table 108. Takeda Latest Developments
Table 109. Merck KGaA Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 110. Merck KGaA Personalized Cancer Medicine Product Offered
Table 111. Merck KGaA Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. Merck KGaA Main Business
Table 113. Merck KGaA Latest Developments
Table 114. Seagen Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 115. Seagen Personalized Cancer Medicine Product Offered
Table 116. Seagen Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Seagen Main Business
Table 118. Seagen Latest Developments
Table 119. Eli Lilly Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 120. Eli Lilly Personalized Cancer Medicine Product Offered
Table 121. Eli Lilly Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Eli Lilly Main Business
Table 123. Eli Lilly Latest Developments
Table 124. Ono Pharmaceutical Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 125. Ono Pharmaceutical Personalized Cancer Medicine Product Offered
Table 126. Ono Pharmaceutical Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Ono Pharmaceutical Main Business
Table 128. Ono Pharmaceutical Latest Developments
Table 129. Pfizer Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 130. Pfizer Personalized Cancer Medicine Product Offered
Table 131. Pfizer Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. Pfizer Main Business
Table 133. Pfizer Latest Developments
Table 134. GSK Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 135. GSK Personalized Cancer Medicine Product Offered
Table 136. GSK Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. GSK Main Business
Table 138. GSK Latest Developments
Table 139. Exelixis Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 140. Exelixis Personalized Cancer Medicine Product Offered
Table 141. Exelixis Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. Exelixis Main Business
Table 143. Exelixis Latest Developments
Table 144. Regeneron Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 145. Regeneron Personalized Cancer Medicine Product Offered
Table 146. Regeneron Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. Regeneron Main Business
Table 148. Regeneron Latest Developments
Table 149. Innovent Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 150. Innovent Personalized Cancer Medicine Product Offered
Table 151. Innovent Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. Innovent Main Business
Table 153. Innovent Latest Developments
Table 154. Hengrui Medicine Details, Company Type, Personalized Cancer Medicine Area Served and Its Competitors
Table 155. Hengrui Medicine Personalized Cancer Medicine Product Offered
Table 156. Hengrui Medicine Personalized Cancer Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Hengrui Medicine Main Business
Table 158. Hengrui Medicine Latest Developments
LIST OF FIGURES
Figure 1. Personalized Cancer Medicine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Personalized Cancer Medicine Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Personalized Cancer Medicine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Personalized Cancer Medicine Sales Market Share by Country/Region (2025)
Figure 8. Personalized Cancer Medicine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Personalized Cancer Medicine Market Size Market Share by Method in 2025
Figure 10. Global Personalized Cancer Medicine Market Size Market Share by Route of Administration in 2025
Figure 11. Global Personalized Cancer Medicine Market Size Market Share by Therapeutic Modality in 2025
Figure 12. Personalized Cancer Medicine in Lung Cancer
Figure 13. Global Personalized Cancer Medicine Market: Lung Cancer (2021-2026) & ($ millions)
Figure 14. Personalized Cancer Medicine in Breast Cancer
Figure 15. Global Personalized Cancer Medicine Market: Breast Cancer (2021-2026) & ($ millions)
Figure 16. Personalized Cancer Medicine in Prostate Cancer
Figure 17. Global Personalized Cancer Medicine Market: Prostate Cancer (2021-2026) & ($ millions)
Figure 18. Personalized Cancer Medicine in Blood-related Cancer
Figure 19. Global Personalized Cancer Medicine Market: Blood-related Cancer (2021-2026) & ($ millions)
Figure 20. Personalized Cancer Medicine in Other
Figure 21. Global Personalized Cancer Medicine Market: Other (2021-2026) & ($ millions)
Figure 22. Global Personalized Cancer Medicine Market Size Market Share by Application in 2025
Figure 23. Global Personalized Cancer Medicine Revenue Market Share by Player in 2025
Figure 24. Global Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Figure 25. Americas Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 26. APAC Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 27. Europe Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 29. Americas Personalized Cancer Medicine Value Market Share by Country in 2025
Figure 30. United States Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Personalized Cancer Medicine Market Size Market Share by Region in 2025
Figure 35. APAC Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Figure 36. APAC Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Figure 37. China Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 41. India Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Personalized Cancer Medicine Market Size Market Share by Country in 2025
Figure 44. Europe Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Figure 45. Europe Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Figure 46. Germany Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 47. France Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Figure 53. Middle East & Africa Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 60. APAC Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 61. Europe Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 63. United States Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 64. Canada Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 65. Mexico Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 66. Brazil Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 67. China Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 68. Japan Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 69. Korea Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 71. India Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 72. Australia Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 73. Germany Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 74. France Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 75. UK Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 76. Italy Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 77. Russia Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 78. Egypt Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 79. South Africa Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 80. Israel Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 81. Turkey Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 82. Global Personalized Cancer Medicine Market Size Market Share Forecast by Method (2027-2032)
Figure 83. Global Personalized Cancer Medicine Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 1. Personalized Cancer Medicine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Personalized Cancer Medicine Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Personalized Cancer Medicine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Personalized Cancer Medicine Sales Market Share by Country/Region (2025)
Figure 8. Personalized Cancer Medicine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Personalized Cancer Medicine Market Size Market Share by Method in 2025
Figure 10. Global Personalized Cancer Medicine Market Size Market Share by Route of Administration in 2025
Figure 11. Global Personalized Cancer Medicine Market Size Market Share by Therapeutic Modality in 2025
Figure 12. Personalized Cancer Medicine in Lung Cancer
Figure 13. Global Personalized Cancer Medicine Market: Lung Cancer (2021-2026) & ($ millions)
Figure 14. Personalized Cancer Medicine in Breast Cancer
Figure 15. Global Personalized Cancer Medicine Market: Breast Cancer (2021-2026) & ($ millions)
Figure 16. Personalized Cancer Medicine in Prostate Cancer
Figure 17. Global Personalized Cancer Medicine Market: Prostate Cancer (2021-2026) & ($ millions)
Figure 18. Personalized Cancer Medicine in Blood-related Cancer
Figure 19. Global Personalized Cancer Medicine Market: Blood-related Cancer (2021-2026) & ($ millions)
Figure 20. Personalized Cancer Medicine in Other
Figure 21. Global Personalized Cancer Medicine Market: Other (2021-2026) & ($ millions)
Figure 22. Global Personalized Cancer Medicine Market Size Market Share by Application in 2025
Figure 23. Global Personalized Cancer Medicine Revenue Market Share by Player in 2025
Figure 24. Global Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Figure 25. Americas Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 26. APAC Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 27. Europe Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Personalized Cancer Medicine Market Size 2021-2026 ($ millions)
Figure 29. Americas Personalized Cancer Medicine Value Market Share by Country in 2025
Figure 30. United States Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Personalized Cancer Medicine Market Size Market Share by Region in 2025
Figure 35. APAC Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Figure 36. APAC Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Figure 37. China Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 41. India Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Personalized Cancer Medicine Market Size Market Share by Country in 2025
Figure 44. Europe Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Figure 45. Europe Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Figure 46. Germany Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 47. France Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Personalized Cancer Medicine Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Personalized Cancer Medicine Market Size Market Share by Method (2021-2026)
Figure 53. Middle East & Africa Personalized Cancer Medicine Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Personalized Cancer Medicine Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 60. APAC Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 61. Europe Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 63. United States Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 64. Canada Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 65. Mexico Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 66. Brazil Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 67. China Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 68. Japan Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 69. Korea Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 71. India Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 72. Australia Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 73. Germany Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 74. France Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 75. UK Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 76. Italy Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 77. Russia Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 78. Egypt Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 79. South Africa Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 80. Israel Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 81. Turkey Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
Figure 82. Global Personalized Cancer Medicine Market Size Market Share Forecast by Method (2027-2032)
Figure 83. Global Personalized Cancer Medicine Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Personalized Cancer Medicine Market Size 2027-2032 ($ millions)
More Publications
Global Intelligent Personal Assistant Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
February 2024
86 pages
Global Personalization Engines Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
December 2024
156 pages
Global E-Commerce Personalization Software Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
146 pages
Global Ecommerce Personalization Tools Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
147 pages
Global Person-to-person Payment Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
112 pages
